In a previous article, I noted that digitization is critical for many cell and gene therapy firms, but few have fully embraced the approach. That was the view of Ori Biotech chief data officer Kevin Gordon.
Other experts agree with Gordon, especially regarding the need for a flexible, digital manufacturing infrastructure, a must for advanced therapy firms looking to scale up production. Advanced therapies, roughly defined as medicines based on gene, tissues, or cells, are a major focus for the biopharmaceutical industry research spending.
